Oblenio has begun dosing patients in its phase 1a first‑in‑human trial of LBL‑051, a tri‑specific T cell engager designed to deplete both B cells and plasma cells in refractory autoimmune diseases. The company said the therapy aims to deliver a durable immune system reset with the potential for sustained drug‑free remission. The open‑label, multicentre study is enrolling patients across multiple autoimmune indications and uses subcutaneous dosing to assess safety, tolerability, clinical response, B cell and plasma cell depletion and selected biomarkers. Tapan Maniar, Chief Medical Officer of Oblenio, explained: “Our phase 1a trial design marks a significant step forward in the clinical development of T cell engagers for autoimmunity. Oblenio recently presented preclinical data at the European Alliance of Associations for Rheumatology 2026 Congress.